CytoDyn CYDY
OTC CYDY
$0.20 +0.00 (+0.00%)
At close: Oct 2, 2026 · 4:00 PM EDT

CytoDyn (CYDY) Accumulated Expenses (2011 - 2018)

Updated

CytoDyn (CYDY) reported Accumulated Expenses of $57,983 for fiscal Q4 2018 (quarter ended May 31, 2018), down 89.6% from the prior quarter.

Analysis

CytoDyn (CYDY) Accumulated Expenses (2011 - 2018) Analysis & Trends

Dating back to fiscal Q4 2011, CytoDyn's Accumulated Expenses record includes 16 quarters.

  • Accumulated Expenses has a five-year compound annual growth rate of -29.0% (FY2013 to FY2018).
  • By fiscal year, Accumulated Expenses came in at $65,000 in FY2014 (-79.8%).
  • The fiscal Q4 2018 figure ranks as the lowest quarterly Accumulated Expenses since fiscal Q1 2015.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn
10 CytoDyn 274.70 Mn 274.70 Mn -
Historic Data

Historic Data

Download Data
DateValue
May 31, 2018 57,983.00
Feb 28, 2018 556,896.00
Feb 28, 2015 127,508.00
Nov 30, 2014 62,627.00
Aug 31, 2014 57,500.00
May 31, 2014 65,000.00
Feb 28, 2014 50,474.00
Nov 30, 2013 46,341.00
Aug 31, 2013 428,051.00
May 31, 2013 321,884.00
Feb 28, 2013 148,900.00
Nov 30, 2012 316,226.00
Aug 31, 2012 123,645.00
May 31, 2012 150,573.00
Aug 31, 2011 756.00
May 31, 2011 756.00
API Access

CytoDyn Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=CYDY&period=max&api_key=YOUR_API_KEY